Brain

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the…

1 year ago

Retrospective clinical study highlights the effectiveness of Curonix’s Freedom® PNS System in reducing pain scores and improving patient satisfaction

POMPANO BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from…

1 year ago

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due…

1 year ago

Enrollment Completed for HOPE PMR Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable MR Imaging® System

Multi-site observational study seeks to redefine the standard of care for pediatric hydrocephalus managementGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the…

1 year ago

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) (“RespireRx”), focused on the…

1 year ago

AlzeCure Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer’s

STOCKHOLM, SWEDEN / ACCESSWIRE / August 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

1 year ago

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in ChicagoChronic SCI cohort results expected in…

1 year ago

American Psychedelic Practitioners Association and BrainFutures Publish First Professional Practice Guidelines for Psychedelic-Assisted Therapy

First-ever set of professional guidelines informed by clinical research and expert consensus will set benchmarks for practitioners in an emerging…

1 year ago

Sparian Biosciences Awarded $19 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-518 for Stimulant Use Disorder Through Phase 1 Clinical Development

SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g.,…

1 year ago